Publications by authors named "David Bodkin"

Claim this Profile
S
Simultaneous Isolation of Circulating Nucleic Acids and EV-Associated Protein Biomarkers From Unprocessed Plasma Using an AC Electrokinetics-Based Platform.
Juan Pablo Hinestrosa, David J Searson, Jean M Lewis, Alfred Kinana, Orlando Perrera, David Bodkin

Front Bioeng Biotechnol· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy.
Karen Kelly, Christopher G Azzoli, Petr Zatloukal, István Albert, Peter Y Z Jiang, David Bodkin

J Thorac Oncol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.
Peter D Boasberg, Charles H Redfern, Gregory A Daniels, David Bodkin, Chris R Garrett

Cancer Chemother Pharmacol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
Thomas J Lynch, David Fenton, Vera Hirsh, David Bodkin, Edward L Middleman

J Thorac Oncol· August 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.
Ronald B Natale, David Bodkin, Ramaswamy Govindan, Bethany G Sleckman, Naiyer A Rizvi

J Clin Oncol· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer.
Charles A Butts, David Bodkin, Edward L Middleman, Craig W Englund, David Ellison

J Clin Oncol· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of paclitaxel poliglumex as first-line chemotherapy in patients at high risk with advanced-stage non-small-cell lung cancer: results of a phase II study.
Donald A Richards, Paul Richards, David Bodkin, Marcus A Neubauer, Fred Oldham

Clin Lung Cancer· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis